The National Company Law Tribunal (NCLT) in Chennai has rejected DBS Bank's lease claim against Orchid Pharma, following a hearing during the Corporate Insolvency Resolution Process (CIRP). This ruling, announced on April 2, 2026, did not affect Orchid Pharma's operational or financial status.

Orchid Pharma's credit rating has been lowered by CARE Ratings to BBB-, while maintaining a stable outlook. The short-term ratings remain at A2. Previous ratings were under review, but have now been reaffirmed.